В первом полугодие 2014г. рынок ста

В первом полугодие 2014г. рынок статинов вырос на 5,2% в упаковках и на 4,7% в деньгах, но в последние месяцы наблюдается отрицательная динамика – рынок сильно падает. Положительную динамику роста и в последние месяцы, и на протяжении всего первого полугодия сохраняют только розувастатины, в основном, за счет дешевых препаратов. Продажи розувастатинов выросли на 42,7% в упаковках и на 26,5% в деньгах.
Доля рынка Мертенила выросла на 11,4% в упаковках и на 3,2% в деньгах. Динамика ухудшилась в последние месяцы и доля Мертенила сильно падает, основная причина – рост цен (на сегодняшний день это самый дорогой генерический розувастатин на рынке). Основными конкурентами остаются Роксера (KRKA,Словения) и Розарт (Актавис, Исландия). Розарт (Актавис, Исландия), как самый дешевый европейский розувастатин, значительно вырос в продажах и в упаковках, и в деньгах (+57,7% и +76,5% соответственно). Значительно выросли продажи препарата Розулип (Егис, Венгрия) - +60,7% в упаковках, и +59,4% в деньгах. Активность по этим препаратам значительно увеличилась, причем это не только визиты к врачам, но и неэтичная промоция (разные программы лояльности для врачей и аптек)

Результаты (английский) 1:

In the first half of 2014. the market grew by 5.2% of statin drugs in packages and to 4.7% in money terms, but in recent months there has been a negative dynamics-the market is falling. Positive dynamics of growth and in recent months, and throughout the first half of the year remain only rozuvastatiny, mainly due to cheap drugs. Sales grew by 42.7% rozuvastatinov in packages and 26.5% in the money.
Market share grew by 11, Mertenila4% in packs and 3.2% in the money. The dynamics have worsened in recent months and the proportion of Mertenila terrible, the main reason is the rise in prices (today it is the most expensive generic rosuvastatin in the market). The main competitors are Roksera (KRKA, Slovenia) and Rozart (Aktavis, Iceland). Rozart (Aktavis, Iceland) as the cheapest European rosuvastatin, has grown in sales and in packages, and money (57,7% and 76.5% respectively). Sales of the drug have increased significantly Rozulip (National, Hungary)-60.7% in packages, and 59.4% in the money. The activity of these drugs has increased considerably, not only visits to doctors, but the unethical promotion (various loyalty programs for doctors and pharmacies)

Результаты (английский) 2:

In the first half of 2014. statins market grew by 5.2% in units and 4.7% in money, but in recent months there has been negative trend - the market drops sharply. Positive growth in recent months, and throughout the first half only retain rosuvastatin, mainly due to cheaper drugs. Rosuvastatin sales rose by 42.7% in units and 26.5% in value.
Merten market share increased by 11.4% in units and 3.2% in cash. Dynamics has deteriorated in recent months and the proportion of Merten drops sharply, the main reason - the rise in prices (today it is the most expensive generic rosuvastatin on the market). The main competitors are Roxer (KRKA, Slovenia) and Rozart (Actavis, Iceland). Rozart (Actavis, Iceland), as the cheapest European rosuvastatin significantly increased sales and in packs, and the money (57.7% and 76.5%, respectively). Significantly increased sales of the drug Rozulip (EGIS, Hungary) - 60.7% in units and 59.4% in value. Activity of these drugs has increased significantly, and this is not only visits to doctors, but also unethical Promotion (various loyalty programs for physicians and pharmacies)

Результаты (английский) 3:

In the first half 2014. market статинов grew by 5.2 per cent in the packages, and at 4.7 per cent in money, but in recent months there has been a negative dynamics - the market severely drops. Positive dynamics of growth and, in recent months,And throughout the first half retain only розувастатины, in the main, the low-cost drugs. Sale розувастатинов rose by 42.7 per cent in packages, and to 26.5 per cent in money.
Market Share Мертенила grew by 11,4% in packages and to 3.2 per cent in money. The Speaker has deteriorated in recent months, and the proportion of Мертенила severely drops, the main reason is the rise in prices (to date, it is the world's most expensive centrifuge розувастатин on the market).The major competitors remain Роксера (Krka,Slovenia) and Розарт (Актавис, Iceland). Розарт (Актавис, Iceland), as well as the cheapest European розувастатин, rose significantly in sales and in packages, and the money ( 57,7 Per cent and 76.5 per cent respectively). There was a significant increase in sales Розулип (Егис, Hungary) - 60.7 per cent in packages, and 59.4 per cent in money. Activity of these drugs has increased significantly, and this is not only visits to doctors,But unethical промоция (different loyalty program for doctors and pharmacies)